Last updated: October 21, 2026
NUCYNTA is a branded tapentadol opioid marketed in the United States by Collegium Pharmaceutical. Its commercial franchise includes immediate-release NUCYNTA tablets and extended-release NUCYNTA ER tablets. The product remains commercially relevant because of its dual mechanism, chronic pain positioning, and limited direct generic competition, but its growth is constrained by opioid prescribing controls, payer pressure, restricted distribution, and mature-product economics.
Collegium acquired NUCYNTA from Depomed in 2017. The company has used NUCYNTA as part of a broader controlled-substance portfolio that also includes Xtampza ER and, before the 2024 Ironshore acquisition, Belbuca. NUCYNTA revenue has generally been stable rather than high-growth, with value driven by price, prescription retention, and the absence of broad generic substitution.
What is NUCYNTA and how does tapentadol compete in the opioid market?
NUCYNTA contains tapentadol hydrochloride, a Schedule II opioid analgesic. Immediate-release NUCYNTA is indicated for acute pain severe enough to require an opioid when alternatives are inadequate. NUCYNTA ER is indicated for severe and persistent pain requiring long-term, around-the-clock opioid treatment.
Tapentadol combines mu-opioid receptor agonism with norepinephrine reuptake inhibition. This differentiates it pharmacologically from conventional opioids such as oxycodone and hydrocodone, although the product remains subject to opioid-class risks, including respiratory depression, misuse, addiction, overdose, and withdrawal.
| Product |
Active ingredient |
Dosage form |
FDA approval |
Primary commercial use |
| NUCYNTA |
Tapentadol HCl |
Immediate-release tablets |
2008 |
Acute and severe pain |
| NUCYNTA ER |
Tapentadol HCl |
Extended-release tablets |
2011 |
Chronic severe pain requiring continuous opioid therapy |
NUCYNTA competes with generic oxycodone, hydromorphone, morphine, tramadol and other opioids. NUCYNTA ER also competes with branded extended-release products, including Xtampza ER, Hysingla ER and branded or generic formulations of other long-acting opioids.
Its principal commercial advantages are:
- A differentiated mechanism combining opioid agonism and norepinephrine reuptake inhibition.
- Use in selected patients who do not respond adequately to, or tolerate, conventional opioids.
- A branded supply and medical-information infrastructure.
- Limited direct substitution from a widely available generic tapentadol product in the U.S. market.
Its commercial constraints are equally material. Tapentadol remains a controlled opioid, and prescribers face heightened scrutiny, state prescribing restrictions, prior authorization, opioid-day limits and institutional formulary controls.
How large is the NUCYNTA market?
NUCYNTA is a specialty branded opioid rather than a mass-market primary-care product. Its market is concentrated in pain specialists, anesthesiology, orthopedics, neurology, hospital systems and selected primary-care practices.
Prescription demand has been affected by the overall contraction in opioid prescribing. CDC data show that U.S. opioid prescribing peaked in 2012 and declined materially through the following decade. The reduction has affected both branded and generic opioids, although products with differentiated mechanisms can retain use in narrower patient populations (Centers for Disease Control and Prevention, 2024).
NUCYNTA’s practical market is shaped by four factors:
- The number of patients requiring opioid therapy after other treatments fail.
- Coverage and prior-authorization policies.
- Prescriber willingness to use tapentadol instead of lower-cost generic opioids.
- Availability of a therapeutically substitutable generic tapentadol product.
NUCYNTA is therefore less exposed to volume growth than to net price, formulary access and franchise retention.
What is the financial trajectory for NUCYNTA?
Collegium does not consistently present NUCYNTA as a standalone public-company segment in the same level of detail as total revenue, but SEC filings and company earnings materials identify NUCYNTA as one of the company’s principal commercial products.
The financial pattern has been mature and relatively stable:
| Period |
Financial direction |
Main driver |
| 2017-2019 |
Portfolio integration and commercial stabilization |
Collegium acquisition and sales-force transition |
| 2020-2021 |
Resilient demand with pandemic-related channel changes |
Chronic pain retention and reduced patient access |
| 2022-2023 |
Mature-product performance |
Pricing, prescription retention and limited direct generic pressure |
| 2024 onward |
Stable-to-declining stand-alone contribution within a larger portfolio |
Broader Collegium diversification and opioid-market contraction |
NUCYNTA has historically generated annual net product sales in roughly the low-to-mid nine-figure range for Collegium. The product is material to the company, but it is not the primary growth engine. Xtampza ER has generally received greater strategic emphasis because of its abuse-deterrent formulation and differentiated extended-release oxycodone positioning.
The economics of NUCYNTA are attractive relative to an unprotected generic product because:
- Manufacturing costs are modest relative to branded net sales.
- The product has an established prescriber base.
- Commercial infrastructure can be shared with other Collegium products.
- Direct generic competition has remained limited.
The principal earnings risks are price concessions, payer restrictions, declining opioid utilization and an eventual generic launch. A generic entrant would likely reduce both price and prescribing persistence, with the largest impact on NUCYNTA IR because immediate-release opioid products are easier for payers to substitute.
When does NUCYNTA lose exclusivity?
NUCYNTA has already passed its original market-exclusivity period. Its commercial protection now depends primarily on patent scope, Orange Book listings, litigation outcomes, regulatory barriers and the practical willingness of generic manufacturers to enter.
The key milestones are:
| Event |
Date |
| FDA approval of NUCYNTA IR |
2008 |
| FDA approval of NUCYNTA ER |
2011 |
| Collegium acquisition from Depomed |
2017 |
| Original five-year NCE exclusivity for NUCYNTA IR |
Expired |
| Original five-year NCE exclusivity for NUCYNTA ER |
Expired |
| Current commercial protection |
Patent and market-structure dependent |
FDA new chemical entity exclusivity is not the current barrier. Tapentadol’s remaining protection has been associated with formulation and extended-release claims rather than continuing regulatory exclusivity.
Patent expiry dates should be evaluated patent by patent because listed patents, pediatric extensions, terminal disclaimers and settlement terms can produce different effective entry dates. The commercially important issue is not simply the earliest nominal patent expiration. It is whether an ANDA applicant can obtain approval with a Paragraph IV certification, whether Collegium sues within the statutory window, and whether a settlement permits launch before the latest listed patent date.
What patents protect NUCYNTA and NUCYNTA ER?
The NUCYNTA estate has included patents covering tapentadol compositions, dosage forms and extended-release formulations. The most commercially relevant protection has been directed to NUCYNTA ER rather than the basic active ingredient alone.
Public FDA Orange Book records have identified NUCYNTA-related patents including patents associated with extended-release tapentadol formulations. The estate has included U.S. Patent Nos. 7,994,332 and 8,337,886, among other patent and regulatory rights reported in product and litigation records. Patent scope and current listing status must be assessed against the latest Orange Book edition and the relevant USPTO records.
| Protection category |
Commercial relevance |
| Active-ingredient claims |
Protect tapentadol itself where valid and enforceable, but generally have earlier expiry |
| Extended-release formulation claims |
Protect NUCYNTA ER release characteristics and dosage-form technology |
| Manufacturing claims |
May delay or complicate direct copying, but are less important if a generic can use a non-infringing process |
| Method-of-use claims |
Can cover chronic pain treatment or specified dosing, but do not necessarily block all generic sales |
| Regulatory exclusivity |
Expired for the original approvals |
Formulation patents are more important than method-of-use patents because an ANDA applicant must show pharmaceutical equivalence and bioequivalence to the reference product. A valid formulation patent can create a direct barrier to an equivalent generic product. A method-of-use patent may be narrower if the generic label can omit the patented indication or dosing instruction.
What is the Orange Book status of NUCYNTA?
NUCYNTA and NUCYNTA ER have been listed in the FDA Orange Book as approved prescription products with associated patent information. Orange Book listings provide the framework for ANDA patent certifications and the 30-month stay triggered by timely patent litigation.
The practical Orange Book analysis has three parts:
- Identify every listed patent and expiration date.
- Determine whether the generic applicant filed Paragraph III, Paragraph IV or Section viii certifications.
- Review any litigation or settlement that changes the effective launch date.
An Orange Book listing does not guarantee that a patent will survive validity or infringement challenges. It does create a regulatory pathway for the reference sponsor to assert patent rights against an ANDA applicant.
Which companies are challenging NUCYNTA generic protection?
Public generic competition in tapentadol has involved the standard ANDA ecosystem, including large generic manufacturers and specialty generic companies that evaluate controlled-substance opportunities. The relevant commercial question is whether an applicant has filed an ANDA for NUCYNTA or NUCYNTA ER and whether the filing generated Paragraph IV litigation.
A generic company can challenge NUCYNTA through:
- A Paragraph IV certification alleging that listed patents are invalid or not infringed.
- A Section viii statement carving out a patented method of use.
- A Paragraph III certification accepting a later patent-expiry date.
- A non-infringing formulation or release profile.
A Paragraph IV filing can lead to a 30-month FDA approval stay if the sponsor sues within 45 days. The stay does not determine the ultimate validity of the patent. It delays approval while litigation proceeds, subject to court decisions and statutory exceptions.
What patent litigation affects NUCYNTA?
The most significant litigation risk is ANDA litigation involving extended-release tapentadol formulations. Such cases typically center on:
- Whether the generic release profile falls within the asserted claims.
- Whether the claims are obvious based on prior art involving opioid extended-release technology.
- Whether the asserted claims adequately describe the formulation.
- Whether the generic’s proposed labeling induces infringement.
- Whether settlement terms provide a licensed entry date.
The commercial effect of litigation can exceed the nominal patent term. A settlement can provide an earlier authorized-generic or generic launch date, while an injunction or favorable validity ruling can preserve branded economics until patent expiration.
A complete litigation assessment requires reviewing current federal docket records, settlement filings and FDA approval data. The existence of an Orange Book patent alone does not establish that NUCYNTA has an enforceable monopoly.
Are biosimilar risks relevant to NUCYNTA?
No. Biosimilar competition is not relevant because NUCYNTA is a chemically synthesized small-molecule drug. Any competitive product would proceed through the ANDA pathway, not the biosimilar pathway under the Biologics Price Competition and Innovation Act.
The relevant threats are:
- Generic tapentadol IR.
- Generic tapentadol ER.
- Therapeutic substitution to oxycodone, tramadol or other generic opioids.
- Non-opioid pain therapies.
- Abuse-deterrent opioid formulations.
- Interventional and digital pain-management alternatives.
How do NUCYNTA and Xtampza ER compare?
| Category |
NUCYNTA |
Xtampza ER |
| Active ingredient |
Tapentadol |
Oxycodone |
| Release type |
IR and ER products |
Extended release |
| Differentiation |
Dual mechanism involving norepinephrine reuptake inhibition |
Abuse-deterrent oxycodone formulation |
| Main use |
Acute and chronic severe pain |
Chronic severe pain |
| Commercial role in Collegium portfolio |
Mature, established product |
Strategic growth and franchise anchor |
| Generic risk |
Direct tapentadol ANDA risk |
Formulation-patent and abuse-deterrence risk |
| Market pressure |
Opioid contraction and payer controls |
Same pressures, partly offset by formulation differentiation |
NUCYNTA has pharmacologic differentiation. Xtampza ER has formulation differentiation. From a portfolio perspective, Collegium has used both products to reduce dependence on a single opioid technology, although neither is insulated from opioid-volume decline.
What generic launch scenarios exist for NUCYNTA?
Scenario 1: No near-term direct generic launch
This outcome preserves NUCYNTA pricing and prescription continuity. It is most favorable for Collegium and can occur if patent litigation, manufacturing complexity or limited expected market size discourages ANDA entry.
Scenario 2: NUCYNTA IR generic entry
Immediate-release generic entry would create the clearest substitution risk. Payers could move tapentadol tablets to generic status quickly, reducing branded volume and net price.
Scenario 3: NUCYNTA ER generic entry after litigation
Extended-release entry could be delayed by formulation patents. If approval follows a Paragraph IV settlement, the launch date may be earlier than the latest nominal patent expiration.
Scenario 4: Authorized generic or licensed entry
A licensed generic could preserve some value for Collegium through supply economics, royalties or an agreed commercial relationship. It would still reduce the branded product’s headline net sales.
What revenue exposure does NUCYNTA create for Collegium?
NUCYNTA is a meaningful but declining-risk asset within a diversified controlled-substance portfolio. The exposure is concentrated in U.S. commercial sales because NUCYNTA’s principal strategic value has been its domestic branded franchise rather than broad global expansion.
Revenue sensitivity is highest under three conditions:
- A generic receives FDA approval and gains preferred formulary placement.
- Payers impose step therapy through lower-cost opioids.
- Opioid prescribing declines faster than price increases can offset volume loss.
The exposure is lower if Collegium continues to share sales, medical and compliance infrastructure across NUCYNTA, Xtampza ER and newer products. The 2024 Ironshore transaction further reduces the company’s dependence on any single opioid brand by adding non-opioid and non-pain assets to the portfolio.
How strong is the NUCYNTA patent estate?
The estate is moderate rather than exceptionally strong. Its value is concentrated in formulation and extended-release protection, not in a broad, long-duration composition-of-matter monopoly. That structure creates several limitations:
- Older patents are vulnerable to validity challenges.
- Formulation claims may be designed around.
- Method-of-use claims may be avoided through label carve-outs.
- Patent expiry is approaching or has passed for important rights.
- A controlled-substance market can attract generic interest but also imposes manufacturing and distribution requirements.
NUCYNTA’s commercial durability has therefore depended on the combined effect of patents, prescriber familiarity, payer positioning and the absence of aggressive generic substitution. Patent rights alone do not explain the product’s performance.
What FDA and regulatory factors affect NUCYNTA?
NUCYNTA remains subject to opioid-specific FDA requirements, including labeling controls, medication guides, postmarketing obligations and the broader opioid Risk Evaluation and Mitigation Strategy. Collegium must also comply with controlled-substance quotas, anti-diversion controls, supply-chain monitoring and promotional restrictions.
Regulatory factors supporting the product include:
- Existing FDA approval for both immediate- and extended-release presentations.
- Established safety and dosing information.
- Prescriber familiarity.
- A recognized clinical position for selected severe-pain patients.
Regulatory factors limiting growth include:
- Schedule II controls.
- Opioid prescribing guidelines.
- State-level prescribing and dispensing limits.
- Prior authorization and quantity restrictions.
- Enforcement scrutiny involving opioid promotion and distribution.
Key Takeaways
- NUCYNTA is a mature branded tapentadol franchise owned and marketed by Collegium Pharmaceutical.
- Its FDA exclusivity has expired; remaining protection depends mainly on patents, Orange Book listings, litigation and settlement terms.
- NUCYNTA’s commercial differentiation is pharmacologic, while Xtampza ER’s differentiation is primarily formulation-based.
- Revenue has been relatively stable but lacks a strong volume-growth engine.
- Immediate-release generic entry would create the fastest and most severe substitution risk.
- Extended-release formulation patents may delay generic entry, but they do not create permanent protection.
- Biosimilar risk is irrelevant because NUCYNTA is a small-molecule drug.
- The largest non-patent risks are opioid-market contraction, payer controls, state prescribing restrictions and therapeutic substitution.
- Collegium’s broader portfolio reduces the company’s dependence on NUCYNTA as newer and non-opioid assets expand.
FAQs About NUCYNTA Market and Patent Risk
Is NUCYNTA still under patent protection?
Some NUCYNTA-related formulation and extended-release patent rights have been listed in FDA records, but the product no longer benefits from original new chemical entity exclusivity. Current protection depends on the specific presentation and the latest Orange Book entries.
Does NUCYNTA have a generic equivalent?
The availability of a generic depends on the specific tapentadol presentation, FDA approval status and commercial launch activity. Generic availability can differ between immediate-release and extended-release tablets.
Is tapentadol safer than oxycodone?
Tapentadol has a different pharmacologic profile, but it remains a Schedule II opioid with serious risks, including respiratory depression, misuse and dependence. Its different mechanism does not eliminate opioid-related safety concerns.
Who owns the NUCYNTA brand?
Collegium Pharmaceutical acquired NUCYNTA from Depomed in 2017 and has marketed the product in the United States.
Can NUCYNTA revenue grow despite declining opioid prescriptions?
Growth would require a combination of favorable pricing, retention in selected patients, improved payer access or reduced generic competition. Broad volume growth is difficult in a contracting opioid market.
References
-
Centers for Disease Control and Prevention. (2024). U.S. opioid dispensing rate maps, 2006-2023. U.S. Department of Health and Human Services.
-
Collegium Pharmaceutical, Inc. (2017). Current report on Form 8-K: Acquisition of NUCYNTA products from Depomed, Inc. U.S. Securities and Exchange Commission.
-
Collegium Pharmaceutical, Inc. (2023). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
Collegium Pharmaceutical, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2008). NUCYNTA prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2011). NUCYNTA ER prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for tapentadol and extended-release formulations. U.S. Department of Commerce.
